Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects

Fundamental and Clinical Pharmacology

Volumn 28, Issue 6, 2014, Pages 690-699

  Sidharta, Patricia N ^a   Diamant, Zuzana ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

CRTH2; Entry into human study; Multiple dose; Pharmacokinetics; Setipiprant; Single dose

Indexed keywords

PLACEBO; SETIPIPRANT; 2-(2-(1-NAPHTHOYL)-8-FLUORO-3,4-DIHYDRO-1H-PYRIDO(4,3-B)INDOL-5(2H)-YL)ACETIC ACID; IMMUNOGLOBULIN RECEPTOR; INDOLE DERIVATIVE; NAPHTHALENE DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CATHETER COMPLICATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG URINE LEVEL; DYSPEPSIA; ELIMINATION HALF-LIFE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; ADOLESCENT; ANTAGONISTS AND INHIBITORS; HALF LIFE TIME; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INDOLES; MALE; NAPHTHALENES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; YOUNG ADULT;

EID: 84920196943     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12079     Document Type: Article

References (37)

1. Arima M., Fukuda T. Prostaglandin D2 receptors DP and CRTH2 in the pathogenesis of asthma. Curr. Mol. Med. (2008) 8 365-375.
2. Satoh T., Moroi R., Aritake K. et al. Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J. Immunol. (2006) 177 2621-2629.
3. Mutalithas K., Guillen C., Day C., Brightling C.E., Pavord I.D., Wardlaw A.J. CRTH2 expression on T cells in asthma. Clin. Exp. Immunol. (2010) 161 34-40.
4. Mandhane S.N., Shah J.H., Thennati R. Allergic rhinitis: an update on disease, present treatments and future prospects. Int. Immunopharmacol. (2011) 11 1646-1662.
5. Pettipher R., Hansel T.T., Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. (2007) 6 313-325.
6. Holgate S.T. The epidemic of asthma and allergy. J. R. Soc. Med. (2004) 97 103-110.
7. Kostenis E., Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol. Med. (2006) 12 148-158.
8. Cosmi L., Annunziato F., Galli M.I.G., Maggi R.M.E., Nagata K., Romagnani S. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur. J. Immunol. (2000) 30 2972-2979.
9. Robinson D.S. Th-2 cytokines in allergic disease. Br. Med. Bull. (2000) 56 956-968.
10. Tanaka K., Hirai H., Takano S., Nakamura M., Nagata K. Effects of prostaglandin D2 on helper T cell functions. Biochem. Biophys. Res. Commun. (2004) 316 1009-1014.
11. Xue L., Gyles S.L., Wettey F.R. et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J. Immunol. (2005) 175 6531-6536.
12. Grunig G., Warnock M., Wakil A.E. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science (1998) 282 2261-2263.
13. Wills-Karp M., Luyimbazi J., Xu X. et al. Interleukin-13: central mediator of allergic asthma. Science (1998) 282 2258-2261.
14. Schratl P., Sturm E.M., Royer J.F. et al. Hierarchy of eosinophil chemoattractants: role of p38 mitogen-activated protein kinase. Eur. J. Immunol. (2006) 36 2401-2409.
15. Gyles S.L., Xue L., Townsend E.R., Wettey F., Pettipher R. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants. Immunology (2006) 119 362-368.
16. Hirai H., Tanaka K., Yoshie O. et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. (2001) 193 255-261.
17. Brozek J.L., Bousquet J., Baena-Cagnani C.E. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol. (2010) 126 466-476.
18. GINA. Global strategy for asthma management and prevention, 2011. Available at http://www.gina.org.
19. Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br. J. Pharmacol. (2008) 153(Suppl 1) S191-S199.
20. Fretz H., Valdenaire A., Pothier J. et al. Identification of 2-(2-(1-naphthoyl)-8-fluoro-3, 4-dihydro-1H-pyrido[4, 3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist. J. Med. Chem. (2013) 56 4899-4911.
21. FDA Guidance for Industry. Food-effect bioavailability and fed bioequivalence studies. December 2002, FDA Guidance for Industry, Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
22. Gough K., Hutchinson M., Keene O. et al. Assessment of dose proportionality: report from the statisticians in the Pharmaceutical Industry/Pharmacokinetics UK joint working party. Drug Inf. J. (1995) 29 1039-1048.
23. Lewis R.A., Austen K.F. Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (1981) 293 103-108.
24. Ulven T., Kostenis E. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin. Ther. Pat. (2010) 20 1505-1530.
25. Chen J.J., Budelsky A.L. Prostaglandin D(2) receptor CRTH2 antagonists for the treatment of inflammatory diseases. Prog. Med. Chem. (2011) 50 49-107.
26. Barnes N., Pavord I., Chuchalin A. et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin. Exp. Allergy (2012) 42 38-48.
27. Lemmer B. Clinical chronopharmacology: the importance of time in drug treatment. Ciba Found. Symp. (1995) 183 235-247; discussion 47-53.
28. Bain G., King C.D., Brittain J. et al. Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2. J. Clin. Pharmacol. (2012) 52 1482-1493.
29. Hoch M., Wank J., Kluge I., Wagner-Redeker W., Dingemanse J. Disposition and metabolism of setipiprant, a selective oral CRTH2 antagonist, in humans. Drugs R D (2013) 13 253-269.
30. Horak F., Zieglmayer P., Zieglmayer R. et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy (2012) 67 1572-1579.
31. Singh D., Cadden P., Hunter M. et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur. Respir. J. (2013) 41 46-52.
32. Straumann A., Hoesli S., Bussmann C. et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy (2013) 68 375-385.
33. Busse W.W., Wenzel S.E., Meltzer E.O. et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J. Allergy Clin. Immunol. (2013) 131 339-345.
34. Lai E., Wenning L.A., Crumley T.M. et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin. Pharmacol. Ther. (2008) 83 840-847.
35. Snell N., Foster M., Vestbo J. Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. Respir. Med. (2013) 107 1722-1730.
36. Array Biopharma. ARRY-502 meets primary and key secondary endpoints in asthma study. Available at: http://investor.arraybiopharma.com/mobile.view?c=123810&v=203&d=1&id=1839862. Accessed November 11, 2013.
37. Gallant M., Beaulieu C., Berthelette C. et al. Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg. Med. Chem. Lett. (2011) 21 288-293.